Organization
Florida Cancer Specialists and Sarah Cannon Research Institute, Sarasota, FL, USA
3 abstracts
2 posters
Abstract
A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC).Org: Sarah Cannon Research Institute/Tennessee Oncology, Daiichi Sankyo Inc., Rutgers Cancer Institue of New Jersey, Highlands Oncology, Washington University School of Medicine,
Abstract
An open-label study to assess the safety and efficacy of naporafenib (ERAS-254) administered with trametinib in previously treated patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations (SEACRAFT-1).Org: Next Oncology Virginia and Virginia Cancer Specialists, Sarah Cannon Research Institute/Tennessee Oncology, University of California Irvine, Comprehensive Cancer Centers of Nevada, Washington University School of Medicine in St Louis,
Abstract
BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation.Org: Florida Cancer Specialists and Sarah Cannon Research Institute, Sarasota, FL, USA, Henri and Belinda Termeer Center for Targeted Therapies, Massachusetts General Hospital, Boston, MA, USA, Massachusetts General Hospital, Columbia University Irving Medical Center, New York, NY, USA, University of Virginia, Charlottesville, VA, USA,